While the dollar amount is small relative to market cap, the coordinated timing and C-suite level of both sellers may signal caution ahead of upcoming earnings or strategic challenges, particularly given AbbVie's reliance on post-Humira revenue transition.
ABBV drugs
ABBV drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $232.33entry
- T+1 · 9mo ago −0.17%α +0.74% · $231.94
- T+5 · 8mo ago −2.91%α −1.70% · $225.58
- T+20 · 8mo ago −9.02%α −1.09% · $211.37
- T+60 · 6mo ago −8.27%α −17.60% · $213.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two AbbVie executives, SVP and EVP, each sold shares in the open market, totaling approximately $2.57 million in proceeds. Both transactions were open-market sales at prevailing prices, with no indication of forced or non-cash dispositions.
Key Financial Metrics
Key Facts
- SVP David Ryan sold 5,230 shares for $1,221,518.80 at $233.56 per share on March 4, 2026
- EVP Perry Siatis sold 5,777 shares for $1,348,987.27 at $233.51 per share on March 2, 2026
- Total open-market sales: $2,570,506.07 across two C-suite executives
- Sales represent 0.00063% of AbbVie's $410.8B market cap
Financial Impact
$2.57 million in open-market sales by two senior executives
Risk Factors
- Perception of insider pessimism despite routine nature of small sales
- Potential for negative market interpretation given lack of offsetting insider buying
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (2 trades, 7d window) | cluster-ABBV-1772834780269 |
Track record
22 reports on ABBV
6 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Dec 2
- Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 29, 202618d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
- Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
- Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers